Two-year data from the AFFIRM Phase III monotherapy trial presented for the first time, showed that treatment with TYSBARI (natalizumab) led to a significant reduction in disability progression…
…the rate of clinical relapses and brain lesions in patients with relapsing forms of multiple sclerosis (MS). These data were presented at the 57th annual American Academy of Neurology (AAN) meeting in Miami Beach, FL.
AFFIRM met all primary and secondary endpoints, including disability progression and relapse rate. TYSABRI treatment was also associated with a low level of immunogenicity.
TYSABRI treatment led to a 42 percent (p=0.0002) reduction in the risk of disability progression compared to placebo. TYSABRI also reduced the rate of clinical relapses by 67 percent (p
